Neuroinflammation catching nanobubbles for microglia-neuron unit modulation against epilepsy

Area of Science:

• Neuroscience
• Nanotechnology
• Pharmacology

Background:

• Epilepsy is a neurological disorder characterized by neuronal hyperexcitability and hypersynchrony.
• Current antiseizure medications are ineffective for nearly one-third of patients and do not address underlying causes.
• Neuroinflammation is increasingly recognized as a key factor in epilepsy pathogenesis.

Purpose of the Study:

• To develop a targeted nanobubble (NB) system for visualizing and treating neuroinflammation in epilepsy.
• To investigate the anti-inflammatory and immunomodulatory effects of S1P@DG-NBs in an epilepsy model.

Main Methods:

• Development of gas-filled nanobubbles (NBs) conjugated with diammonium glycyrrhizinate (DG) drugs and sphingosine-1-phosphate (S1P) molecules (S1P@DG-NBs).
• Utilizing the S1P receptor affinity for targeted delivery to the neuroinflammatory microenvironment.
• Assessing the modulation of inflammation via HMGB1 inhibition and TLR4 pathway downregulation by DG drugs.
• Evaluating the M2 microglia polarization and anti-epileptic effects.

Main Results:

• S1P@DG-NBs demonstrated enhanced targeting to the neuroinflammatory microenvironment of epilepsy.
• DG drugs modulated neuroinflammation by inhibiting HMGB1 and downregulating TLR4 signaling.
• Treatment resulted in the polarization of microglia to an anti-inflammatory M2 phenotype.
• The nanobubble technology facilitated real-time ultrasound visualization of the epileptic brain.
• S1P@DG-NBs ameliorated seizure symptoms by delivering anti-inflammatory and immunomodulatory drugs.

Conclusions:

• S1P@DG-NBs represent a promising theranostic platform for epilepsy, combining targeted drug delivery and real-time imaging.
• This nanotechnology effectively targets neuroinflammation, modulates immune responses, and reduces seizure activity.
• The developed nanobubbles offer a potential new therapeutic strategy for drug-resistant epilepsy.